What Changes in EMA GVP Module III Revision 2?
GVP Module III Revision 2 took effect on 10 September 2026. See what changes for subcontractor oversight, PSMF access, remote inspections, and risk planning.
Clinical Trials in Depression Reveal New R&D Priorities in 2026
Clinical trials in depression reveal a broader R&D landscape, from antidepressants and NMDA approaches to biological data and precision psychiatry.
Ivonescimab Challenges Keytruda Beyond China
Ivonescimab beat pembrolizumab in a Chinese trial. Pharmatica examines what HARMONi-2 means for global clinical development, trial design, and NSCLC treatment.
An Overview of EuroQol EQ-5D: Quality-of-Life Assessment
EuroQol EQ-5D explained: How it measures quality of life, supports QALYs and HTA decisions, and what new EuroQol tools mean for clinical trial strategy.
When Hackers Target the Technology Keeping Medical Products Safe
Find out how Europe’s hacking attacks on refrigeration systems expose risks to medicines, plasma, and supply continuity.
Building Better Paediatric Clinical Trials
We explain why paediatric clinical trials remain underfunded, and how better study design, global collaboration, and new technologies can improve medicines for children.